Dimitri Barski

Dr. Dimitri Barski


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2010 in Brain Pathology
Verified
Journal Article
Closed access
Dimitri BarskiDimitri Barski
Dimitri Barski
MWMarietta Wolter
Marietta Wolter
GRGuido Reifenberger
Guido Reifenberger
MRMarkus J. Riemenschneider
Markus J. Riemenschneider

1 January 2014 in Central European Journal of Urology
Verified
Journal Article
Open access
Dimitri BarskiDimitri Barski
Dimitri Barski
EGEvangelos Georgas
Evangelos Georgas
HGHolger Gerullis
Holger Gerullis
TEThorsten Ecke
Thorsten Ecke
Penile carcinoma has an incidence of 4,000 cases in Europe. The therapy and prognosis depend decisively on the lymph node status. Lymph node metastases are detected in 23-65% cases depending on the histopathological pattern. Due to improved diagnostic methods an early detection of tumor stage is possible. Multimodal therapeutic concepts can offer curability for a subset of patients, even those suffering from advanced disease. Current data on penile cancer based on a selective review of the literature by PubMed and the EAU guidelines 2009. Invasive diagnostic tools, such as fine-needle biopsy (FNB) and dynamic sentinel node biopsy (DSNB), improved the diagnosis of lymph node status considerably and reduced the morbidity in specialized centers. The application of 18F-FDG-PET/CT for metastases detection needs further evaluation due to inconsistent results. Inguinal lymphadenectomy is the therapeutic standard in case of metastases proof. It was possible to reduce the complications due to the new modified operation techniques. Patients with extended lymph node and distant metastases have a poor prognosis. Different systemic polychemotherapy regimes are applied currently and are associated with poor outcome (response rates <50%) and high morbidity. Neoadjuvant chemotherapy is recommended in patients with unresectable and relapsing lymph node metastases. Currently, inconsistent therapy regimens are applied for metastatic penile cancer. Standardization is urgently needed through the development of high-quality studies and long-term registers in order to lower the morbidity and increase the efficiency of diagnosis and therapy.

1 October 2011 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
SSSilvia Selinski
Silvia Selinski
MBMeinolf Blaszkewicz
Meinolf Blaszkewicz
MLMarie-Louise Lehmann
Marie-Louise Lehmann
DODaniel Ovsiannikov
Daniel Ovsiannikov
OMOliver Moormann
Oliver Moormann
KGKlaus Golka
Klaus Golka
Genotyping N-acetyltransferase 2 (NAT2) is of high relevance for individualized dosing of antituberculosis drugs and bladder cancer epidemiology. In this study we compared a recently published tagging single nucleotide polymorphism (SNP) (rs1495741) to the conventional 7-SNP genotype (G191A, C282T, T341C, C481T, G590A, A803G and G857A haplotype pairs) and systematically analysed if novel SNP combinations outperform the latter. For this purpose, we studied 3177 individuals by PCR and phenotyped 344 individuals by the caffeine test. Although the tagSNP and the 7-SNP genotype showed a high degree of correlation (R=0.933, P<0.0001) the 7-SNP genotype nevertheless outperformed the tagging SNP with respect to specificity (1.0 vs. 0.9444, P=0.0065). Considering all possible SNP combinations in a receiver operating characteristic analysis we identified a 2-SNP genotype (C282T, T341C) that outperformed the tagging SNP and was equivalent to the 7-SNP genotype. The 2-SNP genotype predicted the correct phenotype with a sensitivity of 0.8643 and a specificity of 1.0. In addition, it predicted the 7-SNP genotype with sensitivity and specificity of 0.9993 and 0.9880, respectively. The prediction of the NAT2 genotype by the 2-SNP genotype performed similar in populations of Caucasian, Venezuelan and Pakistani background. A 2-SNP genotype predicts NAT2 phenotypes with similar sensitivity and specificity as the conventional 7-SNP genotype. This procedure represents a facilitation in individualized dosing of NAT2 substrates without losing sensitivity or specificity.

20 April 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Dimitri BarskiDimitri Barski
Dimitri Barski
DDD. Y. Deng
D. Y. Deng
Purpose.To evaluate the surgical treatment concepts for the complications related to the implantation of mesh material for urogynecological indications.Materials and Methods.A review of the current literature on PubMed was performed.Results.Only retrospective studies were detected. The rate of mesh-related complications is about 15–25% and mesh erosion is up to 10% for POP and SUI repair. Mesh explantation is necessary in about 1-2% of patients due to complications. The initial approach appears to be an early surgical treatment with partial or complete mesh resection. Vaginal and endoscopic access for mesh resection is favored. Prior to recurrent surgeries, a careful examination and planning for the operation strategy are crucial.Conclusions.The data on the management of mesh complication is scarce. Revisions should be performed by an experienced surgeon and a proper follow-up with prospective documentation is essential for a good outcome.

10 November 2010 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
MLMarie-Louise Lehmann
Marie-Louise Lehmann
SSSilvia Selinski
Silvia Selinski
MBMeinolf Blaszkewicz
Meinolf Blaszkewicz
MOMichael M. Orlich
Michael M. Orlich
DODaniel Ovsiannikov
Daniel Ovsiannikov
KGKlaus Golka
Klaus Golka

25 April 2012 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
SSSilvia Selinski
Silvia Selinski
MLMarie-Louise Lehmann
Marie-Louise Lehmann
MBMeinolf Blaszkewicz
Meinolf Blaszkewicz
DODaniel Ovsiannikov
Daniel Ovsiannikov
OMOliver Moormann
Oliver Moormann
KGKlaus Golka
Klaus Golka